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Abstract
Neither hormone receptor genes nor plasma androgens seem signifi-
cantly altered in female subjects before they became affected by
rheumatoid arthritis (RA) and, therefore, do not seem to play a role as
risk factors for its development. However, serum testosterone levels
are inversely correlated with RA activity and dehydro-epi-
androsterone sulfate (DHEAS) plasma levels are inversely correlated
with both disease duration and clinical severity in patients already
affected by active RA. In particular, gonadal and adrenal androgens
(that is, testosterone and DHEAS) are significantly decreased in
inflamed synovial tissue/fluids during active disease as a conse-
quence of the inflammatory reaction, which supports a pro-inflam-
matory milieu in RA joints. Recently, male gender has been found to
be a major predictor of remission in early RA.
Introduction
The study by Karlson and colleagues in Arthritis Research
and Therapy [1] confirms that neither hormone receptor
genes nor plasma androgens play a role as risk factors for the
development of rheumatoid arthritis (RA), at least in female
subjects. On the contrary, clinical and experimental evidence
seems to support perturbations in peripheral androgen
metabolism and a modulatory role for estrogens in patients
with active and overt RA [2].
Androgens in active rheumatoid arthritis
Clinical and epidemiological evidence supports that androgens
protect more male than female subjects from the develop-
ment of immune-inflammatory diseases [3]. Androgens exert
anti-inflammatory activities, at least at the level of the RA
synovial tissue, which contrast with the immune-enhancer
activities locally exerted by estrogens and their metabolites
[3]. It is well known that serum testosterone levels are
inversely correlated with RA disease activity and dehydro-
epiandrosterone sulfate (DHEAS) levels are inversely
correlated with both disease duration and clinical severity [4].
Recently, male gender has been found to be a major
predictor of remission in early RA [5]. Although disease
activity was not obviously more pronounced in female RA
patients at the onset of disease, the disease course became
markedly worse in women. Disparity in RA remission
frequencies between women and men could not even be
explained by differences in disease duration, age or treatment
with disease-modifying antirheumatic drugs or glucocorti-
coids, but the probability of achieving a treatment response,
at least with methotrexate or anti-TNF drugs, is reduced by
35 to 50% in women [5]. Again, just as in active RA, the
presence of androgens (equivalent to being a male patient)
seems to indicate better prognosis.
It seems, therefore, that the effects of TNF antagonists (and,
generally, anticytokine agents) on the levels of peripheral sex
hormones are exerted more quickly in RA synovial tissue than
in serum. In synovial tissue, TNF antagonists seem to down-
regulate the increased conversion of androgens (anti-inflam-
matory) to estrogens (immune response enhancers) that is
induced by the aromatase complex [6]. As is known, inflam-
matory cytokines, such as TNF, are inducers of the aromatase
complex [4].
The beneficial effects of restoring levels of synovial tissue
androgens might be clinically more evident in male RA
patients because they suffer more intensively from the
inflammation-related decrease of androgens, owing to the
stimulatory action of TNF on the conversion of androgens into
estrogens in synovial tissue [6]. Indeed, men with active RA
have lower synovial fluid testosterone levels and higher levels
of estradiol compared to healthy subjects as a result of
increased synovial tissue production of estrone [7].
Androgen changes in RA: chicken or egg?
The crucial question is: does inflammation lead to reduction
of androgen levels (through conversion) or does the sex
hormonal environment influence inflammation? The answer is
that inflammation clearly downregulates androgen production,
but estrogens, and in particular selected hydroxylated
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estrogen metabolites, enhance the immune-inflammatory
response, at least in RA [8].
Interestingly, treatment with anti-estrogens (that is, toremifene
and tamoxifen) inhibited the differentiation of cultured RA
synovial macrophages into dendritic cells and the capacity of
synovial-macrophage-derived dendritic cells to stimulate
allogeneic T cells [9]. In contrast, a small randomized-
controlled trial of testosterone treatment demonstrated
significantly improved symptoms in men with RA [10].
Therefore, the research questions that Karlson and
colleagues’ results now pose are, in reality, only a further
confirmation that the real higher risk for developing RA and
autoimmune rheumatic diseases in general, based on sex
hormone levels, is to be female because of the related
estrogenic hormonal patterns [1,2].
Adrenal and gonadal androgen relationships
Activation of the hypothalamus-pituitary-adrenal axis by pro-
inflammatory stimuli and chronic stress leads to a parallel
decrease in hypothalamus-pituitary-gonadal axis activity
[2,11]. This can be substantiated by decreased levels of
follicle-stimulating hormone and luteinizing hormone, and it is
even more evident by looking at the levels of serum
testosterone and the serum adrenal androgen DHEAS [2].
During a chronic inflammatory process like active RA, levels
of both serum testosterone and, in particular, serum DHEAS
become lower. Since testosterone and its precursors DHEAS
and DHEA have anti-inflammatory properties, the decline in
levels of these hormones further supports the pro-
inflammatory process.
In the adrenal and gonadal glands, the loss of DHEA and
DHEAS is attributed to a synthetic blockade of the second
step of the enzyme P450c17, again induced by inflammatory
cytokines such as IL1β and TNF. Increased DHEAS levels
during treatment with TNF antagonists in active RA patients
suggest an improved adrenal function [12].
Conclusions
Neither plasma androgens nor hormone receptor genes seem
significantly altered in female subjects that will became
affected by RA; therefore, they do not seem to play a role as
risk factors for the development of RA. However, adrenal and
gonadal androgens, which exert anti-inflammatory activities,
are significantly decreased in inflamed tissues (that is,
synovial fluid) during active RA in both male and female
patients, which supports a pro-inflammatory milieu at least in
RA joints (Figure 1). Interestingly, increased aromatization of
androgens has been demonstrated in cultured synovial cells
from RA patients and the synthesized estrogens are further
converted to pro-proliferative estrogens, such as the 16-
hydroxylated forms of estrone and 17β-estradiol [8].
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